BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

821 related articles for article (PubMed ID: 18695366)

  • 1. Current management of thrombotic thrombocytopenic purpura.
    Kremer Hovinga JA; Meyer SC
    Curr Opin Hematol; 2008 Sep; 15(5):445-50. PubMed ID: 18695366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case of severe ADAMTS13 deficiency presenting as thrombotic thrombocytopenic purpura in pregnancy.
    Nikolaou M; Karakantza M; Adonakis G; Theodorou G; Zoumbos N; Decavalas G
    Med Pregl; 2012; 65(9-10):436-9. PubMed ID: 23214340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura.
    Coppo P; Veyradier A
    Presse Med; 2012 Mar; 41(3 Pt 2):e163-76. PubMed ID: 22265954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update on the pathogenesis and management of acquired thrombotic thrombocytopenic purpura.
    Yarranton H; Machin SJ
    Curr Opin Neurol; 2003 Jun; 16(3):367-73. PubMed ID: 12858075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy.
    Joly BS; Stepanian A; Leblanc T; Hajage D; Chambost H; Harambat J; Fouyssac F; Guigonis V; Leverger G; Ulinski T; Kwon T; Loirat C; Coppo P; Veyradier A;
    Lancet Haematol; 2016 Nov; 3(11):e537-e546. PubMed ID: 27720178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission.
    Peyvandi F; Lavoretano S; Palla R; Feys HB; Vanhoorelbeke K; Battaglioli T; Valsecchi C; Canciani MT; Fabris F; Zver S; Réti M; Mikovic D; Karimi M; Giuffrida G; Laurenti L; Mannucci PM
    Haematologica; 2008 Feb; 93(2):232-9. PubMed ID: 18223285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.
    Sadler JE
    Blood; 2008 Jul; 112(1):11-8. PubMed ID: 18574040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombotic thrombocytopenic purpura in children.
    Loirat C; Coppo P; Veyradier A
    Curr Opin Pediatr; 2013 Apr; 25(2):216-24. PubMed ID: 23422353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of thrombotic thrombocytopenic purpura beyond therapeutic plasma exchange.
    Coppo P; Froissart A;
    Hematology Am Soc Hematol Educ Program; 2015; 2015():637-43. PubMed ID: 26637782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of thrombotic thrombocytopenic purpura.
    Fontana S; Kremer Hovinga JA; Lämmle B; Mansouri Taleghani B
    Vox Sang; 2006 May; 90(4):245-54. PubMed ID: 16635066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous immunoglobulin as an adjunct to plasma exchange for the treatment of chronic thrombotic thrombocytopenic purpura.
    Moore JC; Arnold DM; Leber BF; Clare R; Molnar GJ; Kelton JG
    Vox Sang; 2007 Aug; 93(2):173-5. PubMed ID: 17683362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate®) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor.
    Pandey S; Nakagawa M; Rosenbaum ER; Arnaoutakis K; Hutchins LF; Makhoul I; Milojkovic N; Cottler-Fox M
    J Clin Apher; 2015 Feb; 30(1):50-4. PubMed ID: 25042026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Successful treatment with rituximab in a patient with refractory thrombotic thrombocytopenic purpura refractory to plasma exchange].
    Koshino M; Kudou D; Okoshi Y; Obara N; Simizu S; Mukai HY; Suzukawa K; Hasegawa Y; Kojima H; Nagasawa T; Chiba S
    Rinsho Ketsueki; 2010 Feb; 51(2):127-31. PubMed ID: 20379104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in thrombotic thrombocytopenic purpura.
    Sadler JE; Moake JL; Miyata T; George JN
    Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the inhibitor of ADAMTS13 in thrombotic thrombocytopenic purpura.
    Cataland SR; Wu HM
    Expert Opin Pharmacother; 2007 Mar; 8(4):437-44. PubMed ID: 17309338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombotic thrombocytopenic purpura--the role of ADAMTS13 assay in clinical practice.
    Duraković N; Radonić R; Gasparović V
    Coll Antropol; 2010 Sep; 34(3):1087-91. PubMed ID: 20977108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current insight into thrombotic thrombocytopenic purpura.
    Verbeke L; Delforge M; Dierickx D
    Blood Coagul Fibrinolysis; 2010 Jan; 21(1):3-10. PubMed ID: 19851089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for thrombotic thrombocytopenic purpura.
    Cataland SR; Wu HM
    Curr Opin Hematol; 2005 Sep; 12(5):359-63. PubMed ID: 16093780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of thrombotic thrombocytopenic purpura.
    Coppo P;
    Transfus Clin Biol; 2017 Sep; 24(3):148-153. PubMed ID: 28645643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombotic thrombocytopenic purpura: a moving target.
    Sadler JE
    Hematology Am Soc Hematol Educ Program; 2006; ():415-20. PubMed ID: 17124092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.